Purchase Order 75D30123P17794
Award Date
8/31/23
Potential Completion Date
4/22/25
Potential Value
$295K
Federal Agency
CDC Pittsburgh
Awardee
Element Biosciences, Inc.
Ultimate Awardee
Not listed
NAICS Category
334516 - Analytical Laboratory Instrument Manufacturing
PSC Category
6640 - Laboratory Equipment And Supplies
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92121, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
2
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Centers for Disease Control and Prevention (CDC) awarded a $256,725 firm fixed price purchase order to Element Biosciences, Inc., a small disadvantaged business manufacturer of genetic analysis equipment and tools, for the delivery of an AVITI System next-generation DNA sequencing platform. The contract has a performance period ending on September 30, 2024 and does not utilize a small business set-aside. This award represents one of several federal contracts received by Element...
The federal contract award with ID 75D30124P19758 was made by the Centers for Disease Control and Prevention (CDC) to Element Biosciences, Inc., a manufacturer of genetic analysis equipment and tools. The $115,000.00 firm fixed price purchase order is for the provision of lab equipment and services. The contract has an ultimate completion date of September 22, 2029. No small business set-aside was utilized. Element Biosciences, Inc. has previously received other federal contracts from the U.S....
This is a firm fixed-price purchase order contract awarded by the Centers for Disease Control and Prevention (CDC) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The contract is for the provision of Genomic Sequencing Kits with a ceiling value of $170,641.14 and a performance period ending on August 28, 2024. The contract does not utilize a set-aside designation. Illumina is the prime contractor and has been awarded multiple federal contracts...
This $90,309.09 firm fixed-price purchase order was awarded by the Centers for Disease Control and Prevention (CDC) to Life Technologies Corporation, a subsidiary of Thermo Fisher Scientific, for the delivery of a 3730 DNA sequencer. The contract has no set-aside designation. Life Technologies has extensive experience as a prime contractor supporting federal agencies such as the National Institutes of Health, Department of Defense, and Department of Justice through the provision of specialized...
This is a firm fixed price contract awarded by the Department of Health and Human Services Centers for Disease Control and Prevention to Life Technologies Corporation, a manufacturer of scientific instruments and reagents, for the purchase of a capillary DNA sequencer. The contract has a potential value of $149,990.00 and a completion date of September 15, 2018. The contract was awarded on August 17, 2018 and does not have a set-aside designation. Life Technologies Corporation has served as a...
This is a firm fixed price purchase order service agreement awarded by the Centers for Disease Control and Prevention (CDC) Pittsburgh office, a civilian agency, to Illumina, Inc., a for-profit manufacturer of genomic sequencing systems and reagents. The contract has a ceiling value of $236,726.60 and a period of performance through August 31, 2025. It does not have a set-aside designation. The contract provides for Illumina to furnish genomic sequencing goods and services, likely building on...
This is a firm fixed price purchase order contract awarded by the Centers for Disease Control and Prevention (CDC) to Illumina, Inc. for a MiSeq System, sequencing instrument and associated services. The contract has a ceiling value of $97,020.00 and was awarded on April 13, 2022, with a completion date of July 1, 2022. This contract was not set aside for a specific business type. Illumina is a for-profit manufacturer of genomic sequencing and analysis products, and has experience providing...
This is a firm fixed-price purchase order contract awarded by the Centers for Disease Control and Prevention (CDC) to Illumina, Inc., a manufacturer of genetic sequencing and analysis instruments and reagents, for the maintenance of laboratory equipment. The contract has a ceiling value of $14,329.00 and a performance period ending on July 20, 2024. The award does not utilize any set-aside provisions. Illumina has a history of providing sequencing systems, reagents, and services to support...
This firm fixed-price purchase order contract was awarded by the Centers for Disease Control and Prevention (CDC) Office of Acquisition Services to Illumina, Inc., a for-profit manufacturer of sequencing and array-based genomic analysis solutions. The $98,094.00 contract is for the provision of laboratory equipment, with no set-aside designation. Based on Illumina's past federal contract work, the equipment is likely to include Next-Generation DNA sequencing systems, reagents, and related...
This firm fixed-price purchase order was awarded by the Centers for Disease Control and Prevention (CDC) to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The $85,056.40 contract is for the delivery of laboratory reagents, with an ultimate completion date of July 31, 2022. The contract does not have a set-aside designation. Illumina has previously received federal prime contract and subcontract awards from agencies like the National...